Lilly Oncology Medical's banner
Lilly Oncology Medical's profile picture

Lilly Oncology Medical

@LillyOncMed • 6,550 subscribers

Dedicated to communicating the latest science & disease state education from Lilly Oncology. Intended for U.S. HCPs. Community Guidelines: https://t.co/1q8vAe63mK

Shorts

CURRENTLY ENROLLING: A phase 2 clinical trial evaluating a CDK 4/6 inhibitor + temozolomide versus temozolomide monotherapy in children and young adults with newly diagnosed high-grade Glioma. HCPs - Find trial and enrollment info here:

CURRENTLY ENROLLING: A phase 2 clinical trial evaluating a CDK 4/6 inhibitor + temozolomide versus temozolomide monotherapy in children and young adults with newly diagnosed high-grade Glioma. HCPs - Find trial and enrollment info here:

1,217,025 views

Videos

LIVE
1.2k

Anya Rossi

sweetdream.ai

SweetDream.aiSponsored•Livecam
Streaming Now

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

HD live stream
Exclusive private shows
1.2k viewers online

Free preview available • Premium content

FRAmework-01 | Now Enrolling A Ph3 trial evaluating a FRα-targeting ADC in patients with ovarian cancer. Key details: - Enrolling PSOC and PROC - All FRα expression levels - Allows prior mirvetuximab 👇 Click below for trial and enrollment details
1:45
LillyOncMed's profile picture

FRAmework-01 | Now Enrolling A Ph3 trial evaluating a FRα-targeting ADC in patients with ovarian cancer. Key details: - Enrolling PSOC and PROC - All FRα expression levels - Allows prior mirvetuximab 👇 Click below for trial and enrollment details

Lilly Oncology Medical

2,675,562 views • 4 months ago

Patients with HR+, HER2- metastatic breast cancer (MBC) harboring ≥1 poor prognostic factor have significantly shorter real-world progression free survival and overall survival compared to those with no prognostic factors. 🩺 Click the link below to learn more
1:12
LillyOncMed's profile picture

Patients with HR+, HER2- metastatic breast cancer (MBC) harboring ≥1 poor prognostic factor have significantly shorter real-world progression free survival and overall survival compared to those with no prognostic factors. 🩺 Click the link below to learn more

Lilly Oncology Medical

1,014,069 views • 11 months ago

~3 in 10 patients with node-positive, high-risk, HR+, HER2- #EarlyBreastCancer (EBC) may experience recurrence within 5 years. It is vital to identify these patients and intensify their treatment. Learn more here👉: #BreastCancerResearch #bcsm #ESMO2024
0:47
LillyOncMed's profile picture

~3 in 10 patients with node-positive, high-risk, HR+, HER2- #EarlyBreastCancer (EBC) may experience recurrence within 5 years. It is vital to identify these patients and intensify their treatment. Learn more here👉: #BreastCancerResearch #bcsm #ESMO2024

Lilly Oncology Medical

509,919 views • 1 year ago

Two CDK4/6 inhibitors are approved for select patients w/ high-risk HR+, HER2-#EarlyBreastCancer. Understanding the design of CDK4/6i adjuvant trials can help HCPs optimize treatment plans. #BCSM 📚Explore our library of EBC educational resources here:
1:24
LillyOncMed's profile picture

Two CDK4/6 inhibitors are approved for select patients w/ high-risk HR+, HER2-#EarlyBreastCancer. Understanding the design of CDK4/6i adjuvant trials can help HCPs optimize treatment plans. #BCSM 📚Explore our library of EBC educational resources here:

Lilly Oncology Medical

56,671 views • 1 year ago

No more content to load